美罗培南与亚胺培南西司他丁治疗老年肺部感染患者的疗效与安全性
Efficacy and safety of meropenem and imipenem cilastatin in elderly pulmonary infection
章秀凤 1王晓芳1
作者信息
- 1. 浙江省新昌县人民医院 药剂科,浙江 绍兴 312500
- 折叠
摘要
目的 比较美罗培南与亚胺培南西司他丁治疗老年肺部感染患者的临床疗效和安全性分析.方法 从肺部感染患者中筛选出124例老年病患,随机分为2组,分别给予不同的用药方案,其中对照组的61例患者以亚胺培南西司他丁为治疗药物;研究组的63例患者给予用美罗培南注射治疗,于治疗2周后比较2组患者的病原菌清除率、治疗有效率以及不良反应发生情况.结果研究组的病原菌清除率为(98.41%)明显高于对照组的(88.52%);研究组患者的治疗有效率为98.41%,对照组为93.44%,2组比较差异无统计学意义;研究组不良反应发生率为7.94%,对照组为13.11%,2组比较差异无统计学意义.结论 美罗培南或亚胺培南西司他丁治疗老年患者肺部感染的有效率及不良反应发生情况差异无统计学意义,但美罗培南显著较亚胺培南西司他丁的细菌清除率高.
Abstract
Objective To study and compare the efficacy and safety of meropenem and imipenem cilastatin in the treatment of elderly patients with pulmonary infection.Methods A total of 124 elderly patients with pulmonary infection treated in our hospital were chosen.They were randomly divided into two groups.61 patients in the control group were treated with imipenem cilastatin, and 63 patients in the study group were treated with meropenem injection.After two weeks of treatment, the clearance rate of the pathogens, the effective rate of treatment and the incidence of adverse reactions were compared between the two groups.Results The clearance rate of pathogens in the study group was 98.41%, significantly higher than the control group (88.52%).There was no significant difference in effective rate between the study group (98.41%) and the control group(93.44%).There was no significant difference in incidence of adverse reactions between the study group (7.94%) and the control group (13.11%).Conclusion Meropenem or imipenem cilastatin has similar effective rate and adverse reactions , while meropenem could effectively eradicate bacterial infection in the treatment of pulmonary infection in elderly patients.
关键词
肺部感染/老年患者/美罗培南/亚胺培南西司他丁/临床疗效/安全性Key words
pulmonary infection/elderly patients/meropenem/imipenem cilastatin/clinical efficacy/safety引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据